世界最先端の研究で医学の発展に寄与

2013年

2013年 業績・論文

Yuki H, Ueno S, Tatetsu H, Niiro H, Iino T, Endo S, Kawano Y, Komohara Y, Takeya M, Hata H, Okada S, Watanabe T, Akashi K, Mitsuya H, Okuno Y.

PU.1 is a potent tumor suppressor in classical Hodgkin lymphoma cells.

Blood. 121(6):962-70. 2013.

 

Salcedo Gómez PM, Amano M, Yashchuk S, Mizuno A, Das D, Ghosh AK, Mitsuya H.

GRL-04810 and GRL-05010, Difluoride-Containing Nonpeptidic HIV-1 Protease Inhibitors (PIs) That Inhibit the Replication of Multi-PI-Resistant HIV-1 In Vitro and Possess Favorable Lipophilicity That May Allow Blood-Brain Barrier Penetration.

Antimicrob Agents Chemother. 57(12):6110-21. 2013.

 

Amano M, Tojo Y, Salcedo-Gómez PM, Campbell JR, Das D, Aoki M, Xu CX, Rao KV, Ghosh AK, Mitsuya H.

GRL-0519, A Novel Oxatricyclic-Ligand-Containing Nonpeptidic HIV-1 Protease Inhibitor (PI), Potently Suppresses The Replication of a Wide Spectrum of Multi-PI-Resistant HIV-1 Variants In Vitro.

Antimicrob Agents Chemother. 57(5):2036-46. 2013.

 

Kawano Y, Kikukawa Y, Fujiwara S, Wada N, Okuno Y, Mitsuya H, Hata H.

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells.

Int J Oncol. 43(6):1809-16. 2013.

 

Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H.  

PDK1 inhibition is a novel therapeutic target in multiple myeloma.

Br J Cancer. 108(1):170-8. 2013.

 

Tokunaga K, Yamaguchi S, Iwanaga E, Nanri T, Shimomura T, Suzushima H, Mitsuya H, Asou N.

High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia.

Eur J Haematol. 91(3):201-8. 2013.

 

Taura M, Kariya R, Kudo E, Goto H, Iwawaki T, Amano M, Suico MA, Kai H, Mitsuya H, Okada S.

Comparative analysis of ER stress response into HIV protease inhibitors: lopinavir but not darunavir induces potent ER stress response via ROS/JNK pathway.

Free Radic Biol Med. 65:778-88. 2013.

 

Nishijima T, Gatanaga H, Shimbo T, Komatsu H, Endo T, Horiba M, Koga M, Naito T, Itoda I, Tei M, Fujii T, Takada K, Yamamoto M, Miyakawa T, Tanabe Y, Mitsuya H, Oka S; SPARE study team.

Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus Darunavir/r in patients with suppressed viral load did not result in improvement of ren al function but could sustain viral suppression: a randomized multicenter trial.

PLoS One. 8(8):e73639. 2013.

 

Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.

Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies.

J Med Chem. 56(17):6792-802. 2013.

 

Yedidi RS, Maeda K, Fyvie WS, Steffey M, Davis DA, Palmer I, Aoki M, Kaufman  JD, Stahl SJ, Garimella H, Das D, Wingfield PT, Ghosh AK, Mitsuya H.

P2' Benzene Carboxylic Acid Moiety Is Associated with Decrease in Cellular Uptake: Evaluation of Novel Nonpeptidic HIV-1 Protease Inhibitors Containing P2 bis-Tetrahydrofuran Moiety

Antimicrob Agents Chemother. 57(10):4920-7. 2013.

 

Kirby KA, Michailidis E, Fetterly TL, Steinbach MA, Singh K, Marchand B, Leslie MD, Hagedorn AN, Kodama EN, Marquez VE, Hughes SH, Mitsuya H, Parniak MA, Sarafianos SG.

Effects of Substitutions at the 4' and 2 Positions on the Bioactivity of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine.

Antimicrob Agents Chemother. 57(12):6254-64. 2013.

 

Michailidis E, Ryan EM, Hachiya A, Kirby KA, Marchand B, Leslie MD, Huber AD, Ong YT, Jackson JC, Singh K, Kodama EN, Mitsuya H, Parniak MA, Sarafianos SG.

Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.

Retrovirology. 10:65. 2013.

 

Hachiya A, Reeve AB, Marchand B, Michailidis E, Ong YT, Kirby KA, Leslie MD, Oka S, Kodama EN, Rohan LC, Mitsuya H, Parniak MA, Sarafianos SG.

Evaluation of Combinations of 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine with Clinically Used Antiretroviral Drugs.

Antimicrob Agents Chemother. 57(9):4554-8. 2013.  

 

Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M.

The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors.

J Biol Chem. 288(22):15813-20. 2013.

 

Zhao T, Coutts A, Xu L, Yu J, Ohshima K, Matsuoka M.

HTLV-1 bZIP factor supports proliferation of adult T cell leukemia cells through suppression of C/EBPa signaling.

Retrovirology. 10: 159. 2013.

 

Miura M, Yasunaga J-I, Tanabe J, Sugata K, Zhao T, Ma G, Miyazato P, Ohshima K, Kaneko A, Watanabe A, Saito A, Akari H, Matsuoka M.

Characterization of simian T-cell leukemia virus type 1 in naturally infected Japanese macaques as a model of HTLV-1 infection.

Retrovirology. 10: 118, 2013.

 

Yamamoto-Taguchi N, Satou Y, Miyazato P, Ohshima K, Nakagawa M, Katagiri K, Kinashi T, Matsuoka M.

HTLV-1 bZIP factor induces inflammation through labile Foxp3 expression.

PLoS Pathog. 9: e1003630. 2013.

 

Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y, Ito M, Aihara K, An DS, Koyanagi Y.

HIV-1 Vpr accelerates viral replication during acute infection by exploiting proliferating CD4+ T cells in vivo.

PLoS Pathog, 9: e1003812, 2013.

 

Mizuhara T, Kato T, Hirai A, Kurihara H, Shimada Y, Taniguchi M, Maeta H, Togami H, Shimura K, Matsuoka M, Okazaki S, Takeuchi T, Ohno H, Oishi S, Fujii N.

Structure-activity relationship study of phenylpyrazole derivatives as a novel class of anti-HIV agents.

Bioorg Med Chem Lett. 23:4557-61. 2013.

 

Shimane K, Kawaji K, Miyamoto F, Oishi S, Watanabe K, Sakagami Y, Fujii N, Shimura K, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.

Antimicrob Agents Chemother. 57: 4035-8. 2013.

 

Togami H, Shimura K, Okamoto M, Yoshikawa R, Miyazawa T and Matsuoka M.

Comprehensive in vitro analysis of simian retrovirus 4 susceptibility to antiretroviral agents.

J Virol. 87: 4322-9. 2013.

 

Izumi K, Kawaji K, Miyamoto F, Shimane K, Shimura K, Sakagami Y, Hattori T, Watanabe K, Oishi S, Fujii N, Matsuoka M, Kaku M, Sarafianos SG, Kodama EN.

Mechanism of resistance to S138A substituted enfuvirtide and its application ot peptide design.

Int J Biochem Cell Biol. 45: 908-15. 2013.

 

Ma G, Yasunaga J-I, Fan J, Yanagawa S-I, Matsuoka M.

HTLV-1 bZIP factor dysregulates the Wnt pathways to support proliferation and migration of adult T-cell leukemia cells.

Oncogene. 32: 4222-30. 2013.

 

Nishijima T, Takano M, Ishisaka M, Komatsu H, Gatanaga H, Kikuchi Y, Endo T, Horiba M, Kaneda S, Uchiumi H, Koibuchi T, Naito T, Yoshida M, Tachikawa N, Ueda M, Yokomaku Y, Fujii T, Higasa S, Takada K, Yamamoto M, Matsushita S, Tateyama M, Tanabe Y, Mitsuya H, Oka S, Epzicom-Truvada study team.

Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naïve Japanese patients with HIV-1 infection: a randomized multicenter trial. Intern Med. 52(7):735-44. 2013.

お気軽にお問い合わせください TEL 096-373-5156 受付時間 9:00 - 18:00 [ 土・日・祝日除く ]

  • Facebook
  • Hatena
  • twitter
  • Google+
PAGETOP